BiotechTube

Xeruborbactam Oral Prodrug + Ceftibuten

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bacterial Infections

Conditions

Bacterial Infections

Trial Timeline

Nov 10, 2024 → Mar 31, 2025

NCT ID
NCT06157242

About Xeruborbactam Oral Prodrug + Ceftibuten

Xeruborbactam Oral Prodrug + Ceftibuten is a phase 1 stage product being developed by Shionogi for Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT06157242. Target conditions include Bacterial Infections.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06157242Phase 1Completed

Competing Products

20 competing products in Bacterial Infections

See all competitors
ProductCompanyStageHype Score
ASP3652 + PlaceboAstellas PharmaPhase 2
52
Cefiderocol + Standard of CareShionogiPhase 2
52
Cefiderocol + Standard of Care AntibioticShionogiPhase 1
33
Cefiderocol + Standard of CareShionogiPhase 2
52
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten PlaceboShionogiPhase 1
33
Xeruborbactam + Cefiderocol + Xeruborbactam/Cefiderocol + Dextrose 5% in waterShionogiPhase 1
33
CefiderocolShionogiPre-clinical
23
Cefiderocol + Standard of CareShionogiPhase 2
52
Cefiderocol/XeruborbactamShionogiPhase 1
33
DoripenemJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 3
77
Cefiderocol + Ampicillin-sulbactam + Colistin + MeropenemJohnson & JohnsonApproved
85
doripenemJohnson & JohnsonPhase 3
77
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
52
HRS-8427Jiangsu Hengrui MedicinePhase 1
33
Part A: ATM-AVI Single Dose, Cohorts 1-4 + Part B: Multiple-dose ATM-AVI, Cohorts 1-4AbbViePhase 2
52
DalbavancinAbbViePhase 1
33
V419 + INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad™MerckPhase 3
77
AzaSite + TobramycinMerckPhase 3
77
AzaSiteMerckPhase 3
77

Other Products from Shionogi

Naldemedine + PlaceboApproved
85
Rosuvastatin + HMG CoA inhibitorApproved
85
StatinApproved
85
CefiderocolApproved
85
Duloxetine + Pregabalin + PlaceboApproved
85